Anti-GD2 chimeric antigen receptor (CAR)-modified T cells may be a new and innovative approach for the treatment of pediatric H3-K27M-mutant diffuse midline gliomas.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Jones, C. & Baker, S. J. Nat. Rev. Cancer 14, 651–661 (2014).
Mackay, A. et al. Cancer Cell 32, 520–537 (2017).
Lewis, P. W. et al. Science 340, 857–861 (2013).
Mount, C. W. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0006-x (2018).
Maude, S. L. et al. N. Engl. J. Med. 378, 439–448 (2018).
Ahmed, N. et al. JAMA Oncol. 3, 1094–1101 (2017).
O’Rourke, D. M. et al. Sci. Transl. Med. 9, eaaa0984 (2017).
Brown, C. E. et al. N. Engl. J. Med. 375, 2561–2569 (2016).
Yu, A. L. et al. N. Engl. J. Med. 363, 1324–1334 (2010).
Waligora, M. et al. PLoS Med. 15, e1002505 (2018).
Grasso, C. S. et al. Nat. Med. 21, 827 (2015).
The authors declare no competing interests.
About this article
Cite this article
Ramaswamy, V., Taylor, M.D. CAR T cells for childhood diffuse midline gliomas. Nat Med 24, 534–535 (2018). https://doi.org/10.1038/s41591-018-0031-9